Share Price and Basic Stock Data
Last Updated: January 17, 2026, 12:33 pm
| PEG Ratio | 15.29 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
SMS Pharmaceuticals Ltd, a key player in the pharmaceuticals sector, reported a share price of ₹337 with a market capitalization of ₹3,158 Cr. The company has shown a revenue trajectory that reflects resilience and growth, with total sales standing at ₹522 Cr for FY 2023. This figure marks a slight increase from ₹520 Cr in FY 2022, indicating a steady performance amid industry challenges. The trailing twelve months (TTM) sales reached ₹860 Cr, underscoring a robust revenue generation capability. Quarterly sales have fluctuated, with a notable rise to ₹246 Cr in March 2024 from ₹149 Cr in March 2023, demonstrating a strong recovery. However, the company also experienced a slight dip in sales in June 2023, dropping to ₹135 Cr, which raises questions about seasonality or demand fluctuations within the pharmaceutical market. Overall, SMS Pharmaceuticals’ revenue trends suggest a focus on recovery and potential market expansion.
Profitability and Efficiency Metrics
SMS Pharmaceuticals reported a net profit of ₹81 Cr for the TTM, achieving an impressive profit margin of 8.61% in March 2025. The operating profit margin (OPM) was recorded at 20%, indicating effective cost management strategies, although it shows variability, with a peak of 22% in FY 2022. The company’s return on equity (ROE) stood at 11%, while return on capital employed (ROCE) was reported at 12.2%. The interest coverage ratio (ICR) of 7.83x reflects a strong capability to meet interest obligations, which is favorable in the capital-intensive pharmaceutical sector. However, the cash conversion cycle (CCC) of 238 days indicates potential inefficiencies in working capital management, with inventory days at 238 and debtor days at 95. These figures highlight areas for improvement in operational efficiency, essential for enhancing overall profitability in a competitive market.
Balance Sheet Strength and Financial Ratios
As of March 2025, SMS Pharmaceuticals reported total assets of ₹1,186 Cr, with total liabilities amounting to ₹1,186 Cr, reflecting a balanced financial structure. The company’s reserves have significantly increased to ₹751 Cr, compared to ₹487 Cr in March 2023, showcasing strong retained earnings and financial stability. Borrowings stood at ₹324 Cr, which is manageable given the total equity of ₹664 Cr, resulting in a debt-to-equity ratio of 0.48. This ratio is low compared to typical industry standards, suggesting that SMS Pharmaceuticals is not over-leveraged. The company’s price-to-book value (P/BV) ratio of 2.95x indicates a premium valuation by the market relative to its book value, which can be interpreted as a positive investor sentiment. Additionally, the current ratio of 1.72 reflects adequate liquidity, although a quick ratio of 0.84 suggests potential challenges in meeting short-term liabilities without relying on inventory sales.
Shareholding Pattern and Investor Confidence
Investor confidence in SMS Pharmaceuticals is reflected in its shareholding pattern, with promoters holding a significant 68.07% stake as of September 2025, up from 64.17% in December 2022. This increase demonstrates growing promoter confidence in the company’s prospects. Foreign institutional investors (FIIs) hold a minor 0.28%, while domestic institutional investors (DIIs) increased their stake to 2.88%. The public shareholding has declined to 28.77%, indicating a potential consolidation of ownership among committed shareholders. The number of shareholders has also risen to 34,157, suggesting an expanding retail investor base. This structured shareholding pattern can contribute to stability in the company’s stock performance. However, the low FII participation may signal a need for broader market engagement to enhance liquidity and investor interest.
Outlook, Risks, and Final Insight
Looking ahead, SMS Pharmaceuticals is well-positioned to capitalize on growth opportunities within the pharmaceutical sector, particularly given its robust revenue generation and improving profitability metrics. However, several risks remain, including the significant cash conversion cycle that may hinder operational efficiency and the reliance on a concentrated promoter holding which could affect liquidity. Additionally, fluctuations in quarterly sales and the competitive landscape present ongoing challenges. Should the company enhance its working capital management and engage more effectively with institutional investors, it could improve its market standing. Conversely, failure to address operational inefficiencies or maintain sales growth could hinder its financial performance. Overall, SMS Pharmaceuticals presents a compelling case for investors, but careful monitoring of operational metrics and market conditions will be essential for future success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 205/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,910 Cr. | 356 | 479/192 | 81.0 | 24.3 | 0.19 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 45.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,989.74 Cr | 1,116.46 | 52.28 | 202.18 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 159 | 149 | 149 | 135 | 167 | 161 | 246 | 164 | 197 | 173 | 248 | 196 | 242 |
| Expenses | 146 | 131 | 126 | 109 | 139 | 133 | 212 | 131 | 165 | 140 | 207 | 157 | 194 |
| Operating Profit | 14 | 18 | 23 | 27 | 28 | 29 | 33 | 33 | 32 | 33 | 41 | 39 | 48 |
| OPM % | 9% | 12% | 16% | 20% | 17% | 18% | 14% | 20% | 16% | 19% | 17% | 20% | 20% |
| Other Income | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 |
| Interest | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 4 | 5 | 6 | 6 |
| Depreciation | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | 10 |
| Profit before tax | 1 | 6 | 11 | 13 | 15 | 16 | 22 | 22 | 20 | 23 | 29 | 24 | 34 |
| Tax % | 12% | 22% | 24% | 29% | 21% | 26% | 26% | 25% | 28% | 24% | 29% | 24% | 26% |
| Net Profit | 1 | 5 | 8 | 9 | 12 | 12 | 16 | 16 | 14 | 17 | 21 | 18 | 25 |
| EPS in Rs | 0.09 | 0.59 | 0.95 | 1.10 | 1.42 | 1.44 | 1.88 | 1.93 | 1.68 | 2.03 | 2.33 | 2.05 | 2.68 |
Last Updated: December 29, 2025, 2:32 am
Below is a detailed analysis of the quarterly data for SMS Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 242.00 Cr.. The value appears strong and on an upward trend. It has increased from 196.00 Cr. (Jun 2025) to 242.00 Cr., marking an increase of 46.00 Cr..
- For Expenses, as of Sep 2025, the value is 194.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 157.00 Cr. (Jun 2025) to 194.00 Cr., marking an increase of 37.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 48.00 Cr.. The value appears strong and on an upward trend. It has increased from 39.00 Cr. (Jun 2025) to 48.00 Cr., marking an increase of 9.00 Cr..
- For OPM %, as of Sep 2025, the value is 20.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 20.00%.
- For Other Income, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.00 Cr..
- For Interest, as of Sep 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 6.00 Cr..
- For Depreciation, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 10.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 34.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Jun 2025) to 34.00 Cr., marking an increase of 10.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Jun 2025) to 26.00%, marking an increase of 2.00%.
- For Net Profit, as of Sep 2025, the value is 25.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Jun 2025) to 25.00 Cr., marking an increase of 7.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 2.68. The value appears strong and on an upward trend. It has increased from 2.05 (Jun 2025) to 2.68, marking an increase of 0.63.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:37 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 518 | 587 | 611 | 438 | 463 | 465 | 412 | 563 | 520 | 522 | 709 | 783 | 860 |
| Expenses | 461 | 500 | 522 | 363 | 369 | 375 | 332 | 442 | 405 | 467 | 592 | 643 | 698 |
| Operating Profit | 57 | 86 | 89 | 75 | 93 | 90 | 80 | 121 | 115 | 55 | 117 | 140 | 162 |
| OPM % | 11% | 15% | 15% | 17% | 20% | 19% | 19% | 22% | 22% | 10% | 16% | 18% | 19% |
| Other Income | 2 | 16 | 4 | 1 | 2 | 3 | 5 | 3 | 5 | 5 | 4 | 6 | 6 |
| Interest | 14 | 18 | 17 | 16 | 15 | 12 | 12 | 11 | 19 | 22 | 24 | 19 | 21 |
| Depreciation | 13 | 17 | 19 | 19 | 20 | 19 | 22 | 22 | 32 | 32 | 32 | 34 | 37 |
| Profit before tax | 32 | 67 | 56 | 42 | 60 | 62 | 51 | 91 | 69 | 6 | 66 | 93 | 110 |
| Tax % | 36% | 48% | 26% | 14% | 33% | 34% | 36% | 33% | 1% | 26% | 25% | 27% | |
| Net Profit | 20 | 35 | 42 | 36 | 40 | 41 | 33 | 61 | 68 | 4 | 49 | 68 | 81 |
| EPS in Rs | 2.40 | 4.15 | 4.92 | 4.20 | 4.78 | 4.89 | 3.86 | 7.20 | 8.03 | 0.48 | 5.83 | 7.71 | 9.09 |
| Dividend Payout % | 8% | 5% | 4% | 5% | 5% | 5% | 6% | 4% | 4% | 62% | 7% | 5% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 75.00% | 20.00% | -14.29% | 11.11% | 2.50% | -19.51% | 84.85% | 11.48% | -94.12% | 1125.00% | 38.78% |
| Change in YoY Net Profit Growth (%) | 0.00% | -55.00% | -34.29% | 25.40% | -8.61% | -22.01% | 104.36% | -73.37% | -105.59% | 1219.12% | -1086.22% |
SMS Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 14% |
| 3 Years: | 15% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 16% |
| 3 Years: | 0% |
| TTM: | 24% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 22% |
| 3 Years: | 39% |
| 1 Year: | -31% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 10% |
| 3 Years: | 7% |
| Last Year: | 11% |
Last Updated: September 5, 2025, 1:31 pm
Balance Sheet
Last Updated: December 4, 2025, 2:00 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| Reserves | 213 | 246 | 286 | 254 | 293 | 331 | 359 | 420 | 485 | 487 | 562 | 664 | 751 |
| Borrowings | 167 | 167 | 204 | 149 | 146 | 144 | 157 | 255 | 263 | 254 | 281 | 311 | 324 |
| Other Liabilities | 120 | 119 | 158 | 89 | 72 | 93 | 103 | 147 | 126 | 165 | 217 | 202 | 221 |
| Total Liabilities | 509 | 540 | 656 | 501 | 519 | 577 | 627 | 830 | 883 | 914 | 1,068 | 1,186 | 1,305 |
| Fixed Assets | 247 | 277 | 370 | 290 | 279 | 281 | 280 | 457 | 438 | 412 | 437 | 533 | 517 |
| CWIP | 39 | 29 | 13 | 8 | 8 | 18 | 42 | 7 | 11 | 33 | 30 | 35 | 50 |
| Investments | 6 | 13 | 21 | 37 | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 48 |
| Other Assets | 217 | 221 | 252 | 166 | 187 | 232 | 259 | 321 | 389 | 424 | 556 | 573 | 690 |
| Total Assets | 509 | 540 | 656 | 501 | 519 | 577 | 627 | 830 | 883 | 914 | 1,068 | 1,186 | 1,305 |
Below is a detailed analysis of the balance sheet data for SMS Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
- For Reserves, as of Sep 2025, the value is 751.00 Cr.. The value appears strong and on an upward trend. It has increased from 664.00 Cr. (Mar 2025) to 751.00 Cr., marking an increase of 87.00 Cr..
- For Borrowings, as of Sep 2025, the value is 324.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 311.00 Cr. (Mar 2025) to 324.00 Cr., marking an increase of 13.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 221.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 202.00 Cr. (Mar 2025) to 221.00 Cr., marking an increase of 19.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,305.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,186.00 Cr. (Mar 2025) to 1,305.00 Cr., marking an increase of 119.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 517.00 Cr.. The value appears to be declining and may need further review. It has decreased from 533.00 Cr. (Mar 2025) to 517.00 Cr., marking a decrease of 16.00 Cr..
- For CWIP, as of Sep 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 35.00 Cr. (Mar 2025) to 50.00 Cr., marking an increase of 15.00 Cr..
- For Investments, as of Sep 2025, the value is 48.00 Cr.. The value appears strong and on an upward trend. It has increased from 45.00 Cr. (Mar 2025) to 48.00 Cr., marking an increase of 3.00 Cr..
- For Other Assets, as of Sep 2025, the value is 690.00 Cr.. The value appears strong and on an upward trend. It has increased from 573.00 Cr. (Mar 2025) to 690.00 Cr., marking an increase of 117.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,305.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,186.00 Cr. (Mar 2025) to 1,305.00 Cr., marking an increase of 119.00 Cr..
Notably, the Reserves (751.00 Cr.) exceed the Borrowings (324.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -110.00 | -81.00 | -115.00 | -74.00 | -53.00 | -54.00 | -77.00 | -134.00 | -148.00 | -199.00 | -164.00 | -171.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 39 | 37 | 36 | 18 | 19 | 20 | 43 | 68 | 34 | 104 | 122 | 95 |
| Inventory Days | 90 | 81 | 106 | 114 | 135 | 170 | 191 | 148 | 333 | 243 | 201 | 238 |
| Days Payable | 59 | 58 | 79 | 82 | 49 | 59 | 66 | 70 | 97 | 117 | 130 | 95 |
| Cash Conversion Cycle | 70 | 61 | 63 | 50 | 105 | 131 | 169 | 146 | 270 | 230 | 192 | 238 |
| Working Capital Days | 9 | 19 | 19 | -2 | 27 | 39 | 57 | 48 | 94 | 104 | 85 | 88 |
| ROCE % | 12% | 21% | 16% | 13% | 18% | 16% | 13% | 17% | 12% | 4% | 11% | 12% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 1,859,681 | 0.2 | 59.36 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 8.16 | 5.89 | -0.83 | 7.35 | 7.39 |
| Diluted EPS (Rs.) | 8.16 | 5.89 | -0.83 | 7.35 | 7.39 |
| Cash EPS (Rs.) | 11.48 | 9.54 | 4.25 | 11.82 | 9.83 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 72.15 | 63.36 | 54.40 | 55.56 | 48.50 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 72.15 | 63.36 | 54.40 | 55.56 | 48.50 |
| Revenue From Operations / Share (Rs.) | 88.29 | 83.79 | 61.67 | 61.41 | 66.53 |
| PBDIT / Share (Rs.) | 16.38 | 14.30 | 7.02 | 14.12 | 14.71 |
| PBIT / Share (Rs.) | 12.51 | 10.58 | 3.22 | 10.32 | 12.08 |
| PBT / Share (Rs.) | 10.42 | 7.81 | 0.63 | 8.09 | 10.76 |
| Net Profit / Share (Rs.) | 7.60 | 5.81 | 0.45 | 8.02 | 7.20 |
| NP After MI And SOA / Share (Rs.) | 7.80 | 5.89 | -0.83 | 7.35 | 7.39 |
| PBDIT Margin (%) | 18.55 | 17.07 | 11.37 | 22.99 | 22.11 |
| PBIT Margin (%) | 14.16 | 12.62 | 5.22 | 16.80 | 18.16 |
| PBT Margin (%) | 11.79 | 9.32 | 1.02 | 13.17 | 16.17 |
| Net Profit Margin (%) | 8.61 | 6.93 | 0.74 | 13.05 | 10.82 |
| NP After MI And SOA Margin (%) | 8.83 | 7.02 | -1.35 | 11.96 | 11.10 |
| Return on Networth / Equity (%) | 10.80 | 9.29 | -1.53 | 13.23 | 15.23 |
| Return on Capital Employeed (%) | 13.38 | 12.75 | 4.36 | 13.17 | 16.54 |
| Return On Assets (%) | 5.99 | 4.81 | -0.80 | 7.23 | 7.69 |
| Long Term Debt / Equity (X) | 0.21 | 0.22 | 0.26 | 0.31 | 0.36 |
| Total Debt / Equity (X) | 0.48 | 0.52 | 0.54 | 0.55 | 0.53 |
| Asset Turnover Ratio (%) | 0.71 | 0.74 | 0.60 | 0.61 | 0.78 |
| Current Ratio (X) | 1.72 | 1.62 | 1.61 | 1.92 | 1.59 |
| Quick Ratio (X) | 0.84 | 0.91 | 0.73 | 0.64 | 0.88 |
| Inventory Turnover Ratio (X) | 3.02 | 1.86 | 1.26 | 1.99 | 2.35 |
| Dividend Payout Ratio (NP) (%) | 4.89 | 5.09 | -35.97 | 4.08 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 3.27 | 3.12 | 10.13 | 2.69 | 0.00 |
| Earning Retention Ratio (%) | 95.11 | 94.91 | 135.97 | 95.92 | 0.00 |
| Cash Earning Retention Ratio (%) | 96.73 | 96.88 | 89.87 | 97.31 | 0.00 |
| Interest Coverage Ratio (X) | 7.83 | 5.16 | 2.71 | 6.33 | 11.16 |
| Interest Coverage Ratio (Post Tax) (X) | 4.64 | 3.10 | 1.18 | 4.60 | 6.46 |
| Enterprise Value (Cr.) | 2151.85 | 1748.52 | 734.33 | 1007.49 | 1231.25 |
| EV / Net Operating Revenue (X) | 2.75 | 2.47 | 1.41 | 1.94 | 2.19 |
| EV / EBITDA (X) | 14.82 | 14.44 | 12.36 | 8.43 | 9.88 |
| MarketCap / Net Operating Revenue (X) | 2.41 | 2.13 | 0.93 | 1.53 | 1.87 |
| Retention Ratios (%) | 95.10 | 94.90 | 135.97 | 95.91 | 0.00 |
| Price / BV (X) | 2.95 | 2.81 | 1.06 | 1.69 | 2.57 |
| Price / Net Operating Revenue (X) | 2.41 | 2.13 | 0.93 | 1.53 | 1.87 |
| EarningsYield | 0.03 | 0.03 | -0.01 | 0.07 | 0.05 |
After reviewing the key financial ratios for SMS Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 8.16. This value is within the healthy range. It has increased from 5.89 (Mar 24) to 8.16, marking an increase of 2.27.
- For Diluted EPS (Rs.), as of Mar 25, the value is 8.16. This value is within the healthy range. It has increased from 5.89 (Mar 24) to 8.16, marking an increase of 2.27.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.48. This value is within the healthy range. It has increased from 9.54 (Mar 24) to 11.48, marking an increase of 1.94.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 72.15. It has increased from 63.36 (Mar 24) to 72.15, marking an increase of 8.79.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 72.15. It has increased from 63.36 (Mar 24) to 72.15, marking an increase of 8.79.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 88.29. It has increased from 83.79 (Mar 24) to 88.29, marking an increase of 4.50.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 16.38. This value is within the healthy range. It has increased from 14.30 (Mar 24) to 16.38, marking an increase of 2.08.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.51. This value is within the healthy range. It has increased from 10.58 (Mar 24) to 12.51, marking an increase of 1.93.
- For PBT / Share (Rs.), as of Mar 25, the value is 10.42. This value is within the healthy range. It has increased from 7.81 (Mar 24) to 10.42, marking an increase of 2.61.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 7.60. This value is within the healthy range. It has increased from 5.81 (Mar 24) to 7.60, marking an increase of 1.79.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.80. This value is within the healthy range. It has increased from 5.89 (Mar 24) to 7.80, marking an increase of 1.91.
- For PBDIT Margin (%), as of Mar 25, the value is 18.55. This value is within the healthy range. It has increased from 17.07 (Mar 24) to 18.55, marking an increase of 1.48.
- For PBIT Margin (%), as of Mar 25, the value is 14.16. This value is within the healthy range. It has increased from 12.62 (Mar 24) to 14.16, marking an increase of 1.54.
- For PBT Margin (%), as of Mar 25, the value is 11.79. This value is within the healthy range. It has increased from 9.32 (Mar 24) to 11.79, marking an increase of 2.47.
- For Net Profit Margin (%), as of Mar 25, the value is 8.61. This value is within the healthy range. It has increased from 6.93 (Mar 24) to 8.61, marking an increase of 1.68.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.83. This value is within the healthy range. It has increased from 7.02 (Mar 24) to 8.83, marking an increase of 1.81.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.80. This value is below the healthy minimum of 15. It has increased from 9.29 (Mar 24) to 10.80, marking an increase of 1.51.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.38. This value is within the healthy range. It has increased from 12.75 (Mar 24) to 13.38, marking an increase of 0.63.
- For Return On Assets (%), as of Mar 25, the value is 5.99. This value is within the healthy range. It has increased from 4.81 (Mar 24) to 5.99, marking an increase of 1.18.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.21. This value is within the healthy range. It has decreased from 0.22 (Mar 24) to 0.21, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.48. This value is within the healthy range. It has decreased from 0.52 (Mar 24) to 0.48, marking a decrease of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.71. It has decreased from 0.74 (Mar 24) to 0.71, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.72. This value is within the healthy range. It has increased from 1.62 (Mar 24) to 1.72, marking an increase of 0.10.
- For Quick Ratio (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has decreased from 0.91 (Mar 24) to 0.84, marking a decrease of 0.07.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.02. This value is below the healthy minimum of 4. It has increased from 1.86 (Mar 24) to 3.02, marking an increase of 1.16.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 4.89. This value is below the healthy minimum of 20. It has decreased from 5.09 (Mar 24) to 4.89, marking a decrease of 0.20.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 3.27. This value is below the healthy minimum of 20. It has increased from 3.12 (Mar 24) to 3.27, marking an increase of 0.15.
- For Earning Retention Ratio (%), as of Mar 25, the value is 95.11. This value exceeds the healthy maximum of 70. It has increased from 94.91 (Mar 24) to 95.11, marking an increase of 0.20.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 96.73. This value exceeds the healthy maximum of 70. It has decreased from 96.88 (Mar 24) to 96.73, marking a decrease of 0.15.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.83. This value is within the healthy range. It has increased from 5.16 (Mar 24) to 7.83, marking an increase of 2.67.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.64. This value is within the healthy range. It has increased from 3.10 (Mar 24) to 4.64, marking an increase of 1.54.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,151.85. It has increased from 1,748.52 (Mar 24) to 2,151.85, marking an increase of 403.33.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.75. This value is within the healthy range. It has increased from 2.47 (Mar 24) to 2.75, marking an increase of 0.28.
- For EV / EBITDA (X), as of Mar 25, the value is 14.82. This value is within the healthy range. It has increased from 14.44 (Mar 24) to 14.82, marking an increase of 0.38.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has increased from 2.13 (Mar 24) to 2.41, marking an increase of 0.28.
- For Retention Ratios (%), as of Mar 25, the value is 95.10. This value exceeds the healthy maximum of 70. It has increased from 94.90 (Mar 24) to 95.10, marking an increase of 0.20.
- For Price / BV (X), as of Mar 25, the value is 2.95. This value is within the healthy range. It has increased from 2.81 (Mar 24) to 2.95, marking an increase of 0.14.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has increased from 2.13 (Mar 24) to 2.41, marking an increase of 0.28.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in SMS Pharmaceuticals Ltd:
- Net Profit Margin: 8.61%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.38% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.8% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.64
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.84
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 38.4 (Industry average Stock P/E: 52.28)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.48
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.61%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No. 72, H.No. 8-2-334 / 3 & 4, Road No. 5, Opp. SBI Executive Enclave, Hyderabad Telangana 500034 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ramesh Babu Potluri | Chairman & Managing Director |
| Mr. Vamsi Krishna Potluri | Executive Director |
| Dr. Sunkara Venkata Satya Shiva Prasad | Non Exe.Non Ind.Director |
| Mr. Trilok Potluri | Non Exe.Non Ind.Director |
| Mr. Sarvepalli Srinivas | Ind. Non-Executive Director |
| Mr. Sharvan Kudaravalli | Ind. Non-Executive Director |
| Dr. Suresh Kumar Gangavarapu | Ind. Non-Executive Director |
| Mrs. Shanti Sree Bolleni | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of SMS Pharmaceuticals Ltd?
SMS Pharmaceuticals Ltd's intrinsic value (as of 17 January 2026) is ₹281.62 which is 15.43% lower the current market price of ₹333.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,120 Cr. market cap, FY2025-2026 high/low of ₹360/175, reserves of ₹751 Cr, and liabilities of ₹1,305 Cr.
What is the Market Cap of SMS Pharmaceuticals Ltd?
The Market Cap of SMS Pharmaceuticals Ltd is 3,120 Cr..
What is the current Stock Price of SMS Pharmaceuticals Ltd as on 17 January 2026?
The current stock price of SMS Pharmaceuticals Ltd as on 17 January 2026 is ₹333.
What is the High / Low of SMS Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of SMS Pharmaceuticals Ltd stocks is ₹360/175.
What is the Stock P/E of SMS Pharmaceuticals Ltd?
The Stock P/E of SMS Pharmaceuticals Ltd is 38.4.
What is the Book Value of SMS Pharmaceuticals Ltd?
The Book Value of SMS Pharmaceuticals Ltd is 81.2.
What is the Dividend Yield of SMS Pharmaceuticals Ltd?
The Dividend Yield of SMS Pharmaceuticals Ltd is 0.12 %.
What is the ROCE of SMS Pharmaceuticals Ltd?
The ROCE of SMS Pharmaceuticals Ltd is 12.2 %.
What is the ROE of SMS Pharmaceuticals Ltd?
The ROE of SMS Pharmaceuticals Ltd is 11.0 %.
What is the Face Value of SMS Pharmaceuticals Ltd?
The Face Value of SMS Pharmaceuticals Ltd is 1.00.